What Is AOD-9604?

1. How does AOD-9604 work?

AOD-9604 contains amino acids 177–191 from human growth hormone, with an added tyrosine at the beginning. Together they form a 16-amino-acid peptide. Researchers selected this region to investigate effects on fat metabolism without reproducing the full hormone’s growth effects. Moré and Kenley describe its structure and development rationale.

Lipolysis means breaking stored fat into fatty acids that can be released from fat cells. Lipogenesis means making fat. AOD-9604 research investigated both, but releasing fatty acids does not establish that a person loses body fat over several weeks. That requires measuring the eventual outcome.

In Heffernan and colleagues’ 2001 mouse experiments, 14 days of treatment reduced body weight and fat in obese mice. Changes in beta-3-adrenoceptor expression accompanied the response. Mice missing those receptors did not show the same chronic weight response, although an acute metabolic response remained. The authors concluded that AOD-9604’s lipolytic effects were not mediated directly through those receptors.

Describing AOD-9604 as a proven, selective beta-3 receptor agonist overstates that experiment. Its molecular mechanism remains incompletely understood.

2. What did the human weight-loss trials find?

The main oral trials tested AOD-9604 in adults with obesity. Their results cannot provide a forecast for a lean lifter trying to lose the last few pounds.

The familiar “2.6 kg versus 0.8 kg” claim approximates the early weekly rates multiplied by 12. The difference is roughly 1.8 kg, and the measurement was body weight. Calling it 2.6 kg of fat lost because of AOD-9604 changes both the comparison and the outcome. FDA’s review notes sparse methods and results; the abstract described significance in women at the 1 mg dose.

In the larger trial announcement, the sponsor reported less than 1 kg of additional weight loss after accounting for the diet-and-exercise program in every dose group. It ended obesity development on February 21, 2007. The announcement used 536 as the overall population count; the later safety paper identifies 502 randomized participants.

An early favorable result can justify a larger trial. Once that trial fails, quoting only the first result gives a reader an incomplete estimate of what to expect.

3. Belly fat, fat burning and before-and-after photos

One animal result is particularly easy to misread. In Ng and colleagues’ 2000 Zucker-rat study, treated rats gained 15.8 g over 19 days versus 35.6 g in controls. That was more than a 50% reduction in weight gain. Both groups still gained weight. It was not a 50% loss of body weight or fat.

For lower-belly fat or love handles, a useful human trial would measure the relevant fat depot. A waist measurement alone cannot distinguish fat beneath the skin from fat around the organs. The human evidence above does not establish selective removal of either depot with subcutaneous AOD-9604.

A photograph also cannot isolate the compound’s contribution when calories, training and other drugs change together. If someone starts AOD-9604 and tirzepatide in the same month, their weight change describes the combined experience. It cannot establish how much AOD-9604 added.

There is no established transformation timeline. A study’s 12-week endpoint is a measurement date, not a promise that a visible result will appear by week 12.

4. AOD-9604 dosage, injections and half-life

The oral doses in the trial table are historical research details. No approved weight-loss dose or validated subcutaneous fat-loss schedule follows from them. FDA’s 2024 review found no human information for the proposed subcutaneous or transdermal routes.

Changing the route changes the research question. Swallowed milligrams cannot be translated into injected micrograms by unit conversion. A calculator can convert an amount into a volume; it cannot determine whether that amount is effective or safe. Claims that injections solve the oral trial’s failure require their own controlled human results.

Moré and Kenley’s pig experiment reported an approximately three-minute half-life after intravenous administration. That is a pig IV measurement, so it cannot validate a human subcutaneous half-life or a pre-workout schedule.

Cox and colleagues’ metabolism study identified breakdown products after incubating AOD-9604 in serum and urine. One fragment persisted longer than the parent peptide. Such detection research cannot tell you how long a fat-loss effect lasts. Neither study establishes an optimal fasting window, cycle length or injection frequency.

5. AOD-9604 side effects and safety

The 2013 human safety paper reported no significant IGF-1 increase or deterioration in glucose tolerance. Headaches and gastrointestinal symptoms occurred; higher oral doses in a short study produced more headaches, diarrhea and flatulence. A severe episode of chest tightness during an IV study was considered possibly related to treatment.

Serious events, including cancers, occurred during the longer trials, although investigators did not attribute them to treatment. These observations neither prove that AOD-9604 causes cancer nor establish its long-term safety. Two authors listed Metabolic Pharmaceuticals affiliations; this was a report from the development program, not independent replication.

FDA’s current safety page flags possible immune reactions, peptide impurities and uncertainty about the active ingredient. It also notes serious adverse events with unclear causality. Immunogenicity means the immune system may react to the peptide or related material in a product.

Trial tolerability cannot supply a reliable side-effect rate for a research vial. A purity percentage does not by itself establish sterility, dose accuracy or absence of endotoxins. New chest tightness or breathing difficulty after an injection needs urgent medical assessment.

6. AOD-9604 vs HGH fragment, tesamorelin and GLP-1s

Products described as “HGH frag 176–191” and AOD-9604 are often discussed together. AOD-9604’s defined structure is tyrosine followed by hGH 177–191. Similar names do not establish identical sequences, formulations or clinical effects. A study citation should match the molecule being discussed.

The pooled tesamorelin trials involved 806 participants and found a 15.4% treatment effect on visceral fat at 26 weeks. That percentage describes a particular fat depot, so it cannot be ranked against kilograms of total weight change. No head-to-head winner follows from these separate studies.

The studies reviewed here also do not establish that adding AOD-9604 to a GLP-1 drug preserves muscle or breaks a plateau. Those claims need combination trials with body-composition and functional outcomes. More compounds in a stack also make a new symptom harder to attribute.

7. Does AOD-9604 help cartilage or injury recovery?

Kwon and Park’s 2015 study involved 32 rabbits with experimentally induced knee osteoarthritis. Researchers injected saline, hyaluronic acid, AOD-9604, or both agents directly into the joints. The combination produced better cartilage scores than either agent alone and a shorter period of lameness.

This offers a reason to investigate joint effects. It does not establish faster tendon healing, relief of a lifter’s knee pain or recovery from hard training in humans. An injection into a rabbit joint also cannot validate injecting beneath a person’s skin for recovery.

Calling the result “cartilage regeneration” without naming the animal model and delivery route makes it sound much closer to a treatment than the experiment establishes.

8. FDA status, GRAS claims and tested sport

AOD-9604 has no FDA-approved use. As checked on September 21, 2026, FDA’s safety page lists it among bulk substances whose nominations were withdrawn and retains its safety concerns. A compounding nomination’s administrative status does not establish drug approval.

GRAS means “generally recognized as safe” under specified conditions of food use. FDA explains that framework here. It does not approve an injectable weight-loss product. A GRAS claim also cannot establish efficacy, an injection dose or the quality of a particular vial.

WADA’s 2026 Prohibited List explicitly names AOD-9604 in section S2.2.3. The prohibition applies in and out of competition. A drug can fail an obesity trial and still be prohibited in sport.

9. What to record when evaluating a fat-loss claim

For a useful discussion with a clinician, separate the outcome you wanted from what you measured. Weight, waist, strength and symptoms belong in different fields. Record the measurement method, dates, other medications and changes in food intake or training. A tracking record can preserve those details.

If weight falls while strength declines, include both. If nothing changes, keep that observation too. Before attributing a result to AOD-9604, check whether another treatment or a change in calorie intake started at the same time. A personal log can document an experience; establishing the compound’s added effect still requires a comparison.

10. AOD-9604 FAQ

• Does AOD-9604 work for weight loss?

  An early oral study suggested a modest effect, but the larger OPTIONS trial failed to beat placebo significantly at 12 or 24 weeks. Reliable weight-loss results from subcutaneous use remain unestablished.

• Does AOD-9604 target belly fat?

  The available evidence cannot establish selective loss of lower-belly fat or love handles. An injection near a fat deposit does not demonstrate that the deposit will shrink.

• How long does AOD-9604 take to work?

  No dependable timeline for visible results has been established. Twelve and 24 weeks were trial assessment points; they do not promise a result by either date.

• What is the recommended AOD-9604 dosage?

  There is no approved weight-loss dose or validated subcutaneous fat-loss protocol. Historical oral doses cannot be converted into an injection schedule by changing milligrams to micrograms.

• Does AOD-9604 raise IGF-1?

  The published human safety analysis found no significant IGF-1 increase. That finding does not establish muscle preservation, long-term safety or a fat-loss benefit.

• Can you stack AOD-9604 with tirzepatide?

  The research reviewed here does not establish additional fat loss, muscle preservation or safety from that combination. A result while using both cannot isolate what AOD-9604 contributed.

• Is AOD-9604 FDA-approved or GRAS?

  AOD-9604 has no FDA-approved use. GRAS refers to safety under specified food-use conditions; it does not approve an injectable drug or demonstrate weight-loss efficacy.

• Is AOD-9604 banned in sport?

  Yes. WADA's 2026 Prohibited List names AOD-9604 under S2.2.3, growth hormone analogues and fragments. It is prohibited in and out of competition.

11. Sources